FirstWord

AbCellera will pocket $56 million upfront and could earn close to $800 million in milestones per programme.

A fresh raise worth $17 million will help advance the biotech's preclinical programmes and expand its pharma collaborations.

The biotech is developing antibodies that target pituitary adenylate cyclase-activating polypeptide (PACAP), a distinct but complementary pathway to CGRP inhibition.

Ester Banque joined Moderna as chief commercial officer, while a study published in JAMA Internal Medicine showed that people who received seasonal flu, COVID-19 vaccines had a lower rate of major cardiovascular events.

The multi-year licensing deal will use the Stanford University spinout's lab-in-the-loop AI platform to identify novel candidates.

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory DiseaseRAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TA...

With regulatory findings pending, zasocitinib may have bettered Sotyktu in a Phase III head-to-head study,, but the key question could be how it will fare against Johnson & Johnson's oral IL-23 inhibitor Icotyde (icotrokinra), which has gained early momentum since its launch in March.

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (...

Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company’s Phase 3 sunRIZE study in congenita...

Aarhus, Denmark, 17 June 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announces that further safety an...